Wei Lin

About Wei Lin

Wei Lin, M.D., age 56, has served as Chief Medical Officer of Revolution Medicines (RVMD) since April 2023. He previously was CMO at Erasca (2021–Apr 2023), Head of Development at Nektar Therapeutics (2018–2021), and a Global Development Leader at Genentech; he began his academic career on the faculty at MD Anderson Cancer Center (medical oncology fellowship completed there). Dr. Lin holds a B.A. from Haverford College and an M.D. from Harvard Medical School and currently serves on the board of 2seventy bio (TSVT) . During his tenure, RVMD advanced multiple programs to registrational Phase 3 and reported strong PDAC and NSCLC data; RVMD’s total shareholder return improved markedly in 2024 versus 2023, while the company remains pre-commercial with sizable net losses as it scales clinical programs .

Past Roles

External Roles

Fixed Compensation

Not disclosed for Wei Lin in RVMD’s 2025 proxy (he was not listed among the named executive officers). Company methodology for executives (context): base salary reviewed annually and set competitively; target annual cash incentive weighted heavily to corporate objectives (CEO: 100% corporate; other NEOs: 90% corporate/10% individual) .

Performance Compensation

Company-wide executive incentives are driven primarily by annual corporate goals. For 2024, RVMD assessed two components (R&D and Corporate) and determined corporate achievement at 130% of target, which drove NEO payouts; Wei Lin’s specific payout is not disclosed .

Vesting schedules applied broadly to executive equity awards (context): options vest monthly over 4 years; RSUs vest quarterly over 4 years, subject to continued service .

Equity Ownership & Alignment

• Hedging and pledging prohibited: RVMD’s insider trading policy bars derivative hedging and pledging/margin accounts for all covered persons, including officers .
• Rule 10b5-1 plan: On Dec 23, 2024, Wei Lin adopted a Rule 10b5-1 trading arrangement designed only to sell shares needed to cover tax withholding on RSU vesting after Mar 15, 2025, indicating limited, programmatic selling activity around vesting events .
• Stock ownership amounts and guideline requirements for Wei Lin are not disclosed; beneficial ownership tables in the proxy cover NEOs and directors but do not include the CMO’s specific holdings .

Employment Terms

Wei Lin’s individual employment agreement terms are not disclosed. RVMD discloses standard executive (NEO) severance economics and protections, which indicate alignment with market norms and double‑trigger change‑of‑control treatment:

RVMD also maintains a clawback policy for current/former officers (adopted Nov 2023) requiring recovery of erroneously awarded incentive compensation after a restatement, regardless of misconduct .

Performance & Track Record

• PDAC (pancreatic cancer): Under Lin’s clinical leadership, RVMD reported compelling Phase 1 monotherapy outcomes for diraxonrasib (RMC-6236) in previously treated metastatic PDAC, including median PFS ≈8–9 months and favorable OS trends; Phase 3 RASolute 302 in second-line PDAC began global enrollment (readout expected 2026) .
• PDAC first-line: Early data showed tumor regressions in most patients, with monotherapy ORR 47% and DCR 89%; the diraxonrasib+GNP chemo arm showed ORR 55% and DCR 90%, with acceptable safety. RVMD plans Phase 3 RASolute 303 comparing monotherapy vs combo vs chemo .
• PDAC adjuvant: Phase 3 RASolute 304 initiated; ~500 resected patients post ≥4 months perioperative chemotherapy randomized to observation vs diraxonrasib 300 mg daily for two years; primary endpoint disease‑free survival .
• NSCLC: RVMD initiated RASolve 301 (diraxonrasib vs docetaxel) in previously treated RAS-mutant NSCLC and shared encouraging Phase 1 efficacy (ORR 38% in a matched cohort; median PFS 9.8 months; OS 17.7 months) supporting the registrational path .
• Mutant-selective RAS(ON) assets: Elironrasib (G12C) showed confirmed ORR 42% and DCR 79% in heavily pretreated G12C NSCLC; zoldonrasib (G12D) demonstrated favorable safety and activity in PDAC dose escalation with planned pivotal combinations (incl. doublets) beginning 2026 .

Compensation Peer Group (Benchmarking Context)

RVMD’s 2024 compensation peer group (selected August 2023) includes oncology/biotech names spanning pre‑commercial and commercial peers, e.g., Apellis, Arrowhead, Blueprint Medicines, Cerevel, CRISPR Therapeutics, Cytokinetics, Intellia, Intra‑Cellular, Karuna, Madrigal, Denali, Day One, Relay, SpringWorks, Xencor .

Say‑on‑Pay & Shareholder Feedback

RVMD’s 2024 say‑on‑pay received ~99% approval, reflecting broad investor support for the program design emphasizing “at‑risk” pay and clinical value creation objectives .

Company Performance Context

Investment Implications

• Alignment and governance: Anti-hedging/pledging rules and a clawback policy support long-term alignment; double-trigger change‑of‑control terms and competitive severance reduce transaction‑related retention risk while limiting single‑trigger windfalls .
• Selling pressure: Wei Lin’s Rule 10b5‑1 plan is limited to tax‑withholding sales on RSU vesting, suggesting minimal discretionary selling and largely programmatic liquidity around vest dates .
• Execution and value creation: As CMO, Lin’s oversight of PDAC and NSCLC programs has driven multiple registrational starts and strong early efficacy signals, key to prospective pay‑for‑performance outcomes; durability and Phase 3 success remain the core levers for future compensation realization and equity value .
• Risk: RVMD is pre-revenue with substantial operating losses; clinical/regulatory execution risk and pivotal trial outcomes are the dominant drivers of compensation outcomes and equity value in Lin’s remit .